European Union: Brexit Update

Last Updated: 13 April 2018
Article by Nina O'Sullivan and Natasha Pearman

As the Brexit negotiations continue, the life sciences industry remains vocal. Central to its arguments has been: (1) the need for an agreement that will allow continued co-operation between the UK and the EU27 on the regulation of medicines and medical devices, and which will prevent issues in continued supply to patients across the EU; and (2) an interim arrangement of at least two years to avoid a 'cliff face' outcome.

On 19 March, the EU27 and the UK announced that a number of issues in the draft Withdrawal Agreement had been agreed, alongside a transition (or 'implementation') period which will continue to 31 December 2020. The Withdrawal Agreement remains in draft until all aspects of it have been agreed. Likewise, the transition period will only be approved once all aspects of the Withdrawal Agreement are agreed. The draft Withdrawal Agreement has been colour coded – green to show those aspects that are agreed, yellow to show those where there is political agreement but the legal text needs to be agreed, and white where there is no agreement yet or discussions have not commenced.

The industry will also have welcomed the Prime Minister's 'Road to Brexit' speech in early March where she expressed a commitment that, post-Brexit, "UK and EU regulatory standards will remain substantially similar in the future". Further, she explained that the UK would explore the terms on which it could remain part of the European Medicines Agency, i.e. associate membership, which would mean "investment in new innovative medicines continuing in the UK… these medicines getting to patients faster as firms prioritise larger markets when they start the lengthy process of seeking authorisations. But it would also be good for the EU because the UK regulator assesses more new medicine than any other member state".  However, this would of course mean the ECJ retaining jurisdiction, which has previously been a 'red line' – a point the Prime Minister recognised when she said "… if we agree that the UK should continue to participate in an EU agency the UK would have to respect the remit of the ECJ in that regard."  The Prime Minister further stated that associate membership would "of course … mean abiding by the rules of those agencies and making an appropriate financial contribution".

Meanwhile, in its recently published Report, the House of Commons Health and Social Care Committee has called for the closest possible regulatory alignment with the EU, whilst also recognising the need for contingency planning for a 'no deal' situation, given the EU27's stated position on a sectoral approach to regulatory alignment. 

Industry position papers

Recent examples of the industry continuing to press its points include:

  • The Brexit Health Alliance issuing a paper in January 2018 (Brexit and the impact on patient access to medicines and medical technologies) which called upon both sides to co-operate and reach agreement on an implementation period. The paper highlighted a concerning case study relating to a treatment for prostate cancer which is manufactured in the UK only, but which is sold globally in 80 countries: up to 120,000 patients across Europe could be affected if there were supply issues post-Brexit.
  • The Life Science Industry Coalition issuing a position paper in December 2017 raising the following issues:

    • people and patients should be a primary consideration for the phase two negotiations
    • continued alignment of the intellectual property and legal frameworks
    • regulatory co-operation, including mutual recognition of regulatory activities and quality testing
    • trade and supply: medicines should continue to be able to move between both regions
    • transition period, identified as critical to ensuring patients can continue to access medicines post-Brexit

EMA continues to drill home message: prepare for 'no deal'

In the meantime, the EMA has also updated its Guidance and Q&A document, which are based on the UK being a 'third country' post-Brexit, i.e., on the basis that no deal is reached in relation to continued co-operation. The updated EMA document covers a range of issues not previously covered such as the impact on generic and biosimilar marketing authorisations. It also contains some stark recommendations: for example, it 'strongly recommends' that UK-based applicants of marketing authorisation applications (MAA) should change to a non-UK applicant before submitting the MAA. It has also issued a survey to UK-based holders of centralised marketing authorisations to assess their preparedness for Brexit (the survey closed on 9 February and we will report on the results in due course).  

As for the EMA itself, its new permanent premises in the Zuidas business district of Amsterdam will not be ready for occupation until November 2019, but the Dutch Government has made temporary accommodation available from January 2019 (further details on the relocation can be found on the EMA's recently launched relocation tracking tool).

MHRA materials: more balanced, but recognises need for certainty

In contrast to the EMA's materials, the MHRA's recently issued update to pharmaceutical companies starts from the premise that there is a shared interest in ensuring continuity of supply and a close future partnership. It also noted that the EU27 recognise the importance of a time-limited period in which to provide certainty and continuity to business and to patients.

However, MHRA accepts that businesses need to prepare 'for all outcomes' and it confirms it will publish its 'Day one and longer-term proposals' in the event of no ongoing relationship with EMA networks when appropriate. Its approach in any such scenario would be in line with the following principles:

  • the EU Withdrawal Bill will convert the existing EU legislative framework into UK law on exit, 'so there would be no sudden changes to the UK regulatory framework'
  • it would be 'pragmatic in establishing UK regulatory requirements', would give adequate notice and ensure companies have sufficient time to implement any changed requirements
  • where possible, it would make use of information it already has to complete administrative tasks
  • it would ensure the 'minimum disruption and burden on companies', whilst building on the existing relationship between MHRA and firms

Can the industry get a deal – where others can't?

In December, we held a panel discussion with guest speakers Sir Alasdair Breckenridge (Former Chair, MHRA), Jonathan Mogford (Director of Policy, MHRA), Steve Bates (Chief Executive, BIA) and Sarah Rickwood (Vice-President Thought Leadership (Europe), QuintilesIMS).

Whilst all on the panel recognised the immense challenges ahead, the general mood was one of optimism and positivity about the future of the UK life sciences sector. Indeed, as noted by Mishcon de Reya Partner Rob Murray, "it may just be the one sector that pulls it off'" in terms of reaching an arrangement that works for the UK, EU27, business and patients alike, whilst also navigating the redline of the role of the ECJ – perhaps a Swiss-style relationship model may be the preferred approach.

Jonathan Mogford of the MHRA commented on the unique position of the UK in terms of its contribution to the scientific assessment of medicines and that "the preferred scenario would be continuing pretty closely with what we do at the moment certainly at that scientific level and there is absolutely no reason practically, if the will is there, why the UK couldn't remain around the table participating in those scientific assessments coming up with a shared and agreed view". In any event, as Steve Bates put it at the discussion, it is hoped that: "technology will trump political super-structures".

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions